Clinical trials: Primary Graft Dysfunction
Lung Transplant Failure
Biomolecular Phenotyping of Lung Transplant Recipients
Primary graft dysfunction (PGD) is a common problem after a lung transplant. It's a sudden lung injury that affects around 30% of patients within 72 hours of getting a new lung.
- Trial name
- LUTX_phenotype (NCT06125535)
- Testing
- Sub-phenotyping by biomarkers concentration
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Policlinico Hospital
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Primary Graft Dysfunction
Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction
This is a Phase 2 observational nonrandomized pilot investigation to evaluate the safety and efficacy of Sodium Nitrite administration for the reduction of Primary Graft Dysfunction (PGD) in patients undergoing lung transplant.
- Trial name
- NCT01715883
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gladwin, Mark, MD
Chediak-Higashi Syndrome, Graft Versus Host Disease
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II.
- Conditions
- Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis
- Trial name
- NCT00006056
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fairview University Medical Center
Lung Transplantation
Lung and Diaphragm Ultrasound in the Early Postoperative Course Following Lung Transplantation
This feasibility study tries to define the value of daily Lung and Diaphragm Ultrasound in the early postoperative course following Lung transplantation by comparing its diagnostic accuracy with that of standard of care…
- Trial name
- LUS (NCT04891094)
- Testing
- Ultrasound
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Lung Transplant Failure and Rejection, Primary Graft Dysfunction
CLAD: Finding Biomarkers to Predict Rejection and/ or Outcome After Lung Transplantation
Lung transplantation is the ultimate treatment for end stage lung diseases. Survival after lung transplantation is limited mainly due to the development of chronic allograft dysfunction (CLAD).
- Trial name
- NCT04558333
- Testing
- blood and exhaled breath specimens
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- University Hospital, Antwerp
Liver Failure, Liver Failure, Acute
Use of N-Acetylcysteine During Liver Procurement
Randomized prospective study on the impact on the post-LT outcome by the infusion of N-acetylcysteine (NAC) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for…
- Conditions
- Liver Failure, Liver Failure, Acute, Liver Diseases, Carcinoma, Hepatocellular
- Trial name
- NCT01394497
- Testing
- N-acetylcystein
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Azienda Ospedaliera di Padova
Primary Graft Dysfunction, Lung Transplant; Complications
Perioperative Vitamin C Lung Transplant
This study is being done to determine if parenterally administered ascorbic acid (Vitamin C) given at the time of lung transplant is safe. Vitamin C may be an effective intervention towards primary graft dysfunction (PGD).
- Trial name
- NCT04505878
- Testing
- Vitamin C
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Disorder Related to Lung Transplantation, Brain Death
Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation
The recent introduction of ex-vivo lung perfusion (EVLP) as a tool to evaluate and recondition lungs from marginal donors has opened a new era in the field of lung transplantation.
- Conditions
- Disorder Related to Lung Transplantation, Brain Death, Graft Failure, Primary Graft Dysfunction
- Trial name
- EVLP_MI (NCT01967953)
- Testing
- EVLP Group
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Policlinico Hospital
Primary Graft Dysfunction, Lung Transplantation
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
Primary graft dysfunction (PGD) is a severe lung injury that can occur in the days following lung transplant surgery. The purpose of this study is to identify genetic factors that may put someone at risk for developing PGD.
- Trial name
- NCT00457847
- Where
- United States
- Volunteers
- 1,150 people
- Sponsor
- University of Pennsylvania
Lung Transplant
Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation
The purpose of this study is to take a population of lung transplant recipients who meet UCLA criteria for induction chemotherapy with thymoglobulin and prospectively study weather giving the first dose intraoperatively versus…
- Trial name
- NCT00592306
- Testing
- thymoglobulin (intraoperative), thymoglobulin (postoperative)
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
This single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (PH).
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Lung Disease-Associated Pulmonary Hypertension, Lung Transplantation
- Trial name
- NCT06605326
- Testing
- Subcutaneous Treprostinil
- Volunteers
- 46 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Lung Transplant Failure
Lung PGD Biomarkers in Organ Donors
PGD is a syndrome characterized by alveolocapillary barrier structural and functional alterations with surfactant inactivation and vascular permeability increase, which cause lung edema, parenchymal infiltrate and progressive…
- Trial name
- NCT03089489
- Testing
- lung biomarkers in organ donor for PGD in lung recipient
- Volunteers
- 50 people
- Sponsor
- University Hospital of Mont-Godinne
Lung Transplantation
Point-of-care Management of Coagulopathy in Lung Transplantation
Pulmonary transplantation is a very demanding surgical procedure, often accompanied by coagulopathy and severe perioperative bleeding.
- Trial name
- NCT03598907
- Testing
- Fresh frozen plasma
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital, Motol
Ischemia-Reperfusion Injury, Lung Transplantation
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
The objective of this clinical study was to evaluate whether CXCL8 (CXC ligand 8 [formerly interleukin (IL)-8]) inhibition with repertaxin leads to reduced severity of primary graft dysfunction, as the result of improved…
- Trial name
- NCT00224406
- Testing
- Repertaxin
- Where
- 6 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Dompé Farmaceutici S.p.A
Primary Graft Dysfunction, Lung Transplantation
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
Lung transplant recipient survival lags other solid organ recipients, with the main early cause of death being primary graft dysfunction (PGD).
- Conditions
- Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
- Trial name
- MARAVIROC (NCT06853223)
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Primary Graft Dysfunction
Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction
The goal of this clinical trial is to test the feasibility of the study protocol comparing a novel temperature control system - Xo Port Organ Preservation System - to static ice for heat preservation for Heart Transplant.
- Trial name
- PROTECT-PGD (NCT07230886)
- Testing
- Xo Port Organ Preservation System, Standard of Care - Ice packs
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Lung Transplant Rejection, Primary Graft Dysfunction
Exhaled Breath Particles in Lung Transplantation
Lung transplantation (LTx) is the only effective treatment for patients with end stage lung disease. Of the major organs transplanted, survival following LTx is the lowest with a mean of 5 years.
- Conditions
- Lung Transplant Rejection, Primary Graft Dysfunction, Chronic Rejection of Lung Transplant
- Trial name
- NCT05375149
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Lung Transplant; Complications, Primary Graft Dysfunction
Identifying Optimal PEEP After Lung Transplantation
Lung Transplantation (LuTX) is the curative treatment for selected patients with end-stage lung disease. Primary Graft Dysfunction (PGD), a specific form of respiratory failure occurring within the first 72 hours after graft…
- Trial name
- PEEP-LuTX (NCT05691205)
- Testing
- PEEP
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- Policlinico Hospital